NewAmsterdam Pharma Company N.V. (KH6.F) News
Track canonical SquawkNews coverage tagged to KH6.F, NewAmsterdam Pharma Company N.V.. This hub brings together deduplicated headlines about frankfurt, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
NewAmsterdam Pharma dosed first participant in SPINOZA Phase 2b trial of obicetrapib
NewAmsterdam Pharma dosed the first participant in SPINOZA, a Phase 2b trial of obicetrapib in preclinical Alzheimer’s disease. The 52-week study tracks whether treatment shifts Alzheimer’s-related blood biomarkers; abou
EARNINGS | Sep 29, 2026, 12:06 PM UTC
M
NewAmsterdam Pharma's cholesterol drugs Ubeslo, Evlarco get EU approval
The European Commission has granted marketing authorization for NewAmsterdam Pharma's Ubeslo and Evlarco, the company's obicetrapib-based low-density lipoprotein cholesterol therapies. This marks the first global approva
EQUITY | Sep 21, 2026, 04:13 PM UTC